STOCK TITAN

Acer Therapeutics Inc. - ACER STOCK NEWS

Welcome to our dedicated news page for Acer Therapeutics (Ticker: ACER), a resource for investors and traders seeking the latest updates and insights on Acer Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Acer Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Acer Therapeutics's position in the market.

-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.85%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.17%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-33.33%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.48%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
none
Acer Therapeutics Inc.

Nasdaq:ACER

ACER Rankings

ACER Stock Data

16.15M
18.37M
13.78%
29.91%
2.02%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Newton

About ACER

acer therapeutics is a biotech company, headquartered in cambridge, ma, that develops repurposed and reformulated medicines for the treatment of ultra-orphan diseases with significant unmet medical needs. acer's lead candidate, edviso™ (celiprolol), is the first pharmaceutical therapy seeking approval for patients with vascular-type ehlers-danlos syndrome (veds). ehlers-danlos syndrome is a group of hereditary disorders of connective tissue with no ethnic predisposition. veds is a subtype characterized by severe arterial dissections, ruptures and early death. complications are rare in childhood, but affect 25% of patients before the age of 20, and 80% by the age of 40. median age of death is estimated to be around 50 years. patients are diagnosed by clinical symptoms and confirmed by presence of mutations in the col3a1 gene. there are approximately 2,000 documented patients, but prevalence could be as high as 5,000 patients in the u.s. (pepin 2014). there are no specific pharmacologica